Figure 1.

Effect of vinblastine on midazolam clearance (Cl; L/h) and area under the curve (AUC) (ng·h/mL per mg). Data were obtained from 6 patients treated with vinblastine as a 72-hour intravenous infusion every 28 days. Midazolam (0.0145 mg/kg, intravenous bolus) was used as a CYP3A4 phenotyping probe on day 1 of cycle 1 (period 1) and on day 1 of cycle 4 (period 2). A nonparametric 2-sided Wilcoxon signed-rank test was used to assess the differences in medians.